Gary A Lyons Neurocrine Biosciences Inc (NBIX) insider trading activity

NBIX Quotes by TradingView

Gary A Lyons is Director of NEUROCRINE BIOSCIENCES INC. Currently has a direct ownership of 119,047 shares of NBIX, which is worth approximately $16.1 Million. The most recent transaction as insider was on May 17, 2024, when has been sold 2,100 shares (Common Stock) at a price of $0.0 per share, resulting in proceeds of $0. This information was disclosed in a Form 4 filing with the Securities and Exchange Commission (SEC).

Shares Held (Direct Ownership) 119K
38.54% 3M change
41.56% 12M change
Total Value Held $16.1 Million

GARY A LYONS Transaction History

Date Transaction Value Shares Traded Shares Held Form
May 17 2024
BUY
Exercise of conversion of derivative security
-
2,100 Added 1.73%
119,047 Common Stock
May 14 2024
SELL
Open market or private sale
$1,695,375 $135.63 p/Share
12,500 Reduced 9.66%
116,947 Common Stock
May 14 2024
BUY
Exercise of conversion of derivative security
$534,500 $42.76 p/Share
12,500 Added 8.81%
129,447 Common Stock
Dec 22 2023
SELL
Open market or private sale
$1,300,400 $130.04 p/Share
10,000 Reduced 4.91%
193,697 Common Stock
Dec 01 2023
SELL
Open market or private sale
$583,850 $116.77 p/Share
5,000 Reduced 2.4%
203,697 Common Stock
Dec 01 2023
BUY
Exercise of conversion of derivative security
$64,900 $12.98 p/Share
5,000 Added 2.34%
208,697 Common Stock
Sep 12 2023
SELL
Open market or private sale
$575,100 $115.02 p/Share
5,000 Reduced 2.4%
203,697 Common Stock
Sep 12 2023
BUY
Exercise of conversion of derivative security
$64,900 $12.98 p/Share
5,000 Added 2.34%
208,697 Common Stock
Sep 01 2023
SELL
Open market or private sale
$550,300 $110.06 p/Share
5,000 Reduced 2.4%
203,697 Common Stock
Sep 01 2023
BUY
Exercise of conversion of derivative security
$64,900 $12.98 p/Share
5,000 Added 2.34%
208,697 Common Stock
Oct 31 2022
SELL
Open market or private sale
$1,721,400 $114.76 p/Share
15,000 Reduced 6.86%
203,697 Common Stock
Oct 31 2022
BUY
Exercise of conversion of derivative security
$190,650 $12.71 p/Share
15,000 Added 6.42%
218,697 Common Stock
Oct 04 2022
SELL
Open market or private sale
$552,700 $110.54 p/Share
5,000 Reduced 2.4%
203,697 Common Stock
Apr 25 2022
SELL
Open market or private sale
$1,391,400 $92.76 p/Share
15,000 Reduced 6.71%
208,697 Common Stock
Apr 25 2022
BUY
Exercise of conversion of derivative security
$99,900 $6.66 p/Share
15,000 Added 6.28%
223,697 Common Stock
Oct 07 2021
SELL
Open market or private sale
$525,300 $105.06 p/Share
5,000 Reduced 2.34%
208,697 Common Stock
Jun 10 2021
SELL
Open market or private sale
$1,002,700 $100.27 p/Share
10,000 Reduced 4.47%
213,697 Common Stock
Jan 26 2021
SELL
Open market or private sale
$48,000 $120.0 p/Share
400 Reduced 0.18%
223,697 Common Stock
Jan 25 2021
SELL
Open market or private sale
$192,048 $120.03 p/Share
1,600 Reduced 0.71%
224,097 Common Stock

Also insider at

HGEN
HUMANIGEN, INC Healthcare
Director
BBI
Brickell Biotech, Inc. Healthcare
Director
TVTX
Travere Therapeutics, Inc. Healthcare
RIGL
RIGEL PHARMACEUTICALS INC Healthcare
ELDN
Eledon Pharmaceuticals, Inc. Healthcare
Director
GAL

Gary A Lyons

Director
South San Francisco, CA

Track Institutional and Insider Activities on NBIX

Follow NEUROCRINE BIOSCIENCES INC and customize your updates to receive the information that matters most to you.

Institutional Portfolio Updates

Receive a notification when an Institution or Guru buys or sells NBIX shares.

Notify only if

Insider Trading

Get notified when an Neurocrine Biosciences Inc insider buys or sells NBIX shares.

Notify only if

News

Receive news related to NEUROCRINE BIOSCIENCES INC

Choose your preferred platform and Sign Up 👇 Telegram Email
Track Activities on NBIX